On Saturday March 15th, Wilson Sonsini partner Eva Yin will speak at the Digital Fluency: Neurosurgery conference in Palo Alto, CA. She, alongside fellow panelists, will discuss regulatory shifts in technology and AI, including FDA oversight, during their panel, "Rules, Regulations and Uncharted Territory in Ai & Data: Opportunities for Legislative & Oversight Engagement." To learn more about the event and to register, please visit the event website.
Hannah Hebertson
hhebertson@wsgr.com
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.